Henry Fernandez steps down from Royalty Pharma board

Henry Fernandez stepped down from Royalty Pharma plc's (NASDAQ: RPRX) Board of Directors on August 13, 2025, the company announced. Fernandez served as Lead Independent Director since March 2021 and joined the board in July 2020.

Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma, said Fernandez's experience as a public company chief executive and business acumen proved valuable during the company's initial years as a public company. Legorreta cited Fernandez's role in helping the company complete its internalization process.

Fernandez stated that Royalty Pharma has executed its strategy well since its 2020 initial public offering and established itself in the biopharma royalty market. The company plans to name a new Lead Independent Director.

Royalty Pharma, founded in 1996, purchases biopharmaceutical royalties and funds innovation across the industry. The company's portfolio includes royalties on more than 35 commercial products and 16 development-stage product candidates, according to the press release.

You May Also Be Interested In

• T-Mobile (TMUS) Tops Q2 EPS by 27c; offers outlook
• Safari Flower, Aurora Cannabis unit, gets EU-GMP cert in Ontario
• Phreesia and March of Dimes partner on maternal health education